Potential adenovirus-mediated gene therapy of glioma cancer

Abstract

Malignant gliomas are typically characterized by rapid cell proliferation and a marked propensity to invade and damage surrounding tissues. They are the main brain tumors notoriously resistant to currently available therapies, since they fail to undergo apoptosis upon anticancer treatments. With recent advances in neuroscience and improved understanding of the molecular mechanisms of invasive migration, gene therapy provides a new strategy for treating glioma cancer. Brain tumor gene therapy using viral vectors and stem cells has shown promise in animal model and human patient studies. Here, we review recent studies on engineering adenoviral vectors that can be used as therapy for brain tumors. The new findings presented in this study are essential for the further exploration of this cancer and they represent an approach for developing a newer and more effective therapeutic approach in the clinical treatment of human glioma cancer.

Histological characteristics and markers of proliferation and differentiation in rat brain with experimental glioma

“…This study used animals in which tumor had been developing for 21-25 days, unlike other authors who used this model, however with tumor development lasting for 10-11 days 16 , 14 days 17 , or 11-21 days 18 following the cerebral implantation of C6 cells.…”

Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19

“…The study results suggested that poxvirus can be a promising platform when used with different antigen targets, in combination with checkpoint inhibitor, or in other disease settings (Gulley et al, 2019). Adenoviruses, when used in animal models (Lundstrom, 2017), have shown potential therapeutic effects for gastric cancer, hepatic carcinoma, prostate (Ekblad and Halldén, 2010), ovarian (Matthews et al, 2009), and brain cancer (Fu et al, 2010). Shapira et al demonstrated that adenoviral vectors encoding a proapoptotic PUMA gene regulated by RAS-responsive elements (Ets/AP1) can suppress the growth of cancer cell with KRAS mutation (Shapira et al, 2017).…”

New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy

“…Ads represent the most frequently used viral vectors subjected to cancer therapy. For instance, animal models for ovarian, 44 prostate, 45 gastric, 46 and brain cancer 47 have been established. Related to gastric cancer, expression of RPL23 and p53 from a bicistronic Ad vector provides significantly better tumor-suppression activity in gastric cancer cells and antitumor responses in MKN45 cells compared to administration of the Ad-p53 vector alone.…”